Komori
ReproCELL (4978) · InitiativeRestated

Contracting partnership for an influenza clinical development project with VIROCLINICS DDL

First written in FY2021-Q2. 2 of 3 entries say "Restated". Latest entry: FY2021.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021-Q2 – FY20212020: 120202021: 22021
Same theme, other companies
Expanding the Evidence Solutions BusinessA theme 9 companies write about · 2 as a headwind · 10 as a tailwind

The whole theme swung hardest in 2020: 1 of 8 companies on the "Worse" side.

2 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2021RestatedAnnual report

    「We agreed with VIROCLINICS-DDL (headquartered in the Netherlands) to partner on a clinical development project conducted by the company and are providing contract services for an influenza clinical development project from September 2020 to April 2021.」

    The provision of contract services for an influenza clinical development project under the partnership with VIROCLINICS-DDL has been reaffirmed.
  2. FY2021-Q3RestatedAnnual report

    「During the nine-month period ended in the third quarter, we agreed with VIROCLINICS DDL (headquartered in the Netherlands) to partner on a clinical development project conducted by the company. Under this partnership, we will provide contract services for an influenza clinical development project from September 2020 to April 2021.」

    The plan to provide contract services for an influenza clinical development project from September 2020 through April 2021 under the partnership with VIROCLINICS DDL has been reaffirmed.
  3. FY2021-Q2First statedAnnual report

    「During the six-month period ended in the second quarter, we agreed with VIROCLINICS DDL (headquartered in the Netherlands) to partner on a clinical development project conducted by the company. Under this partnership, we will provide contract services for an influenza clinical development project from September 2020 to April 2021.」

    A new research support service project was launched with VIROCLINICS DDL of the Netherlands to provide contract services for an influenza clinical development project from September 2020 through April 2021.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for ReproCELL yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Contracting partnership for an influenza clinical development project with VIROCLINICS DDL | ReproCELL Incorporated (4978) | Komori